Gland Pharma stock (INE068V01023): earnings report due May 15, 2026

Gland Pharma is set to release quarterly earnings on May 15, 2026, with analyst consensus expecting EPS of $16.25. The Indian pharmaceutical manufacturer trades on NSE and BSE.

Gland Pharma Ltd., an India-based injectable and ophthalmic pharmaceutical manufacturer, is scheduled to report earnings on Friday, May 15, 2026, according to StockInvest as of May 14, 2026. Analyst consensus for the expected earnings per share stands at $16.25 for the reporting period.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gland Pharma Ltd.
• Sector/industry: Pharmaceuticals & Drugs, Healthcare
• Headquarters/country: Hyderabad, Telangana, India
• Core markets: Injectable and ophthalmic pharmaceuticals, generic drugs
• Home exchange/listing venue: NSE (GLAND), BSE (543245)
• Trading currency: Indian Rupee (?)
• Market capitalization: ?30,384 crore (as of May 14, 2026)

Gland Pharma: core business model

Gland Pharma operates as a manufacturer of injectable and ophthalmic pharmaceuticals with significant generic drug operations. The company is headquartered in Hyderabad, India, and serves both domestic and international markets. Its product portfolio focuses on injectable formulations and ophthalmic solutions, positioning it within the broader injectable drug delivery market, which is expected to reach US $1,258.40 billion according to OpenPR market analysis.

Earnings catalyst and investor focus

The May 15, 2026 earnings release represents a key catalyst for the stock. With analyst consensus targeting EPS of $16.25, investors will scrutinize revenue growth, margin performance, and guidance for upcoming quarters. The company's recent stock performance showed a gain of 0.454% on May 2, 2025, rising from ?1,398.35 to ?1,404.70, according to market data.

Conclusion

Gland Pharma's upcoming earnings report on May 15, 2026 will provide clarity on the company's financial performance and operational trajectory. As a significant player in the injectable pharmaceutical market, the company's results will be closely monitored by investors tracking exposure to the growing global demand for injectable drug delivery systems. The consensus EPS estimate of $16.25 sets a benchmark for assessing whether the company is meeting market expectations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.